Abstract
Introduction The discovery of novel gene–disease associations remains a cornerstone of advances in medicine,1 including in nephrology, where genetic insights have reshaped our understanding of kidney diseases.2 Accordingly, reports proposing new monogenic kidney disorders often generate substantial interest. To determine if such associations are truly causal requires systematic evaluation of phenotype, genotype, and, where available, experimental data. Frameworks such as that developed by the Clinical Genome Resource emphasize several core principles: clear and reproducible phenotyping, concordant genetic evidence across unrelated individuals, allele frequencies compatible with disease prevalence and inheritance, and experimental data that are biologically consistent with the proposed mechanism.3 Importantly, functional evidence alone, no matter how elegant, cannot establish causality when the supporting human genetic data are not robust.4 Here, we briefly outline these principles and apply them to a recent report by Peng and colleagues, using it as a case study to illustrate the insights gained when gene–disease claims are evaluated rigorously. Applying These Principles: The Case of ATP6V0A4 p.V512L With these principles in mind, we turn to the recent report by Peng et al., which describes a father–son dyad with hypochloremic metabolic alkalosis and hypokalemia attributed to a gain-of-function (GOF) variant in ATP6V0A4.5 This proposal is striking because it is well known that recessive loss-of-function ATP6V0A4 variants cause distal renal tubular acidosis (dRTA) type 3, characterized by impaired urinary acidification, hypochloremic metabolic acidosis, and hypokalemia.6 A GOF mechanism producing the opposite phenotype—metabolic alkalosis—would represent a reversal of established ATP6V0A4 biology, and therefore, it warrants especially careful clinical and genetic evaluation. In-Depth Genetic Analyses Are Critical Establishing a novel gene–disease association begins with a rigorous and transparent assessment of the genetic evidence. This includes demonstrating that the proposed causal variant is both sufficiently rare and appropriately concordant with the observed phenotype, requirements emphasized in Clinical Genome Resource's clinical validity framework. Against this backdrop, the genetic analyses presented by Peng et al. warrant closer scrutiny. Using whole-exome sequencing, the authors identified a heterozygous variant in ATP6V0A4 (p.V512L) that they describe as novel. However, they do not describe how novelty was assessed, nor how other candidate variants were excluded. A standard first step is to query large population databases, such as gnomAD, to determine if it was previously reported in patients and if its minor allele frequency (MAF) is compatible with the estimated prevalence and inheritance pattern. While the prevalence of the new disorder is unknown, it is presumably rarer than recessive dRTA, with an estimated prevalence of 1:100,000.7 There are 14 heterozygous individuals among 807,097 gnomAD participants who harbor the variant p.V512L (rs752903587). This corresponds to a MAF of 1.6×10−5 (approximately 1:50,000). When these data are stratified by ancestry, we find an even higher MAF among East Asian individuals: 1.33×10−4 (approximately 1:10,000). MAFs in this range are difficult to reconcile with a rare autosomal dominant condition. Five of these 14 carriers also appear in the All of Us (AoU) Research Program database, which provides genotype-linked clinical data extracted from electronic medical records. Although detailed clinical data were available for only two of five individuals, neither has documented overt kidney disease, reinforcing the population-level observation that p.V512L is probably not strongly associated with the expected kidney phenotype. Finally, it is important to note that the authors' detailed analysis showing that in silico predictions label p.V512L as a pathogenic variant is not helpful, as these predictions primarily inform loss-of-function mechanisms and offer little insight into GOF effects.8 When Dealing with Renal Tubulopathies, Accurate Physiologic Phenotyping Is Key Both individuals had mild alkalemia with serum bicarbonate at the upper limit of normal and acidic urine (Table 1). The father has a slightly negative urine anion gap, which is compatible with inappropriate net acid excretion while alkalotic. Table 1 - Biochemical data for the patients from Peng et al.5 and the two subjects from All of Us Characteristics Proband Father All of Us Participant 1 All of Us Participant 2 Reference Ranges Sex Male Male Male Female Age 32 ? 32 29 pH 7.47 7.46 N/A N/A 7.35–7.45 PaCO2 40 39 N/A N/A 35–45 mm Hg HCO3 28 27 N/A N/A 21–28 mmol/L Na 132 138 140 140 137–147 mmol/L K 1.7 3.3 3.6 3.6 3.5–5.5 mmol/L Cl 89 95 105 105 99–110 mmol/L SAG 12 12 11 14 10–20 mmol/L TCO2 [28] [27] 28 25 22–27 mmol/L Creatinine 4.5 0.7 1.1 0.7 0.6–1 μmol/L Urine pH 5 5.5 N/A 6 and 6.5 Depends on acid load Urine K (24 h) N/A 32 N/A N/A